

Radha Rajasingham

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/253894/radha-rajasingham-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

3,851
citations

22
h-index

62
g-index

70
ext. papers

4,985
ext. citations

8.1
avg, IF

5.48
L-index

#	Paper	IF	Citations
64	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofaa602	1	3
63	Reply to Neves. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1772-e1774	11.6	2
62	Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0086021	9.7	0
61	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021 , 72, e835-e843	11.6	59
60	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , 2021 , 21, 16-18	25.5	5
59	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021 , 22, 1266	1.4	2
58	Impact of biological sex on cryptococcal meningitis mortality in Uganda and South Africa. <i>Medical Mycology</i> , 2021 , 59, 712-719	3.9	
57	Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. <i>Medical Mycology</i> , 2020 , 58, 1037-1043	3.9	4
56	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2020 , 67, 1201-1211	3	15
55	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 517-525	59.2	803
54	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 766-769	6.1	34
53	Evaluation of Serum Cryptococcal Antigen Testing Using Two Novel Semiquantitative Lateral Flow Assays in Persons with Cryptococcal Antigenemia. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	16
52	Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa530	1	0
51	Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 2020 ,		8
50	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial 2020 ,		17
49	Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2020 , 71, 525-531	11.6	7
48	Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy-Experienced Ugandans With Virologic Failure. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1726-1731	11.6	5

47	Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. <i>Clinical Infectious Diseases</i> , 2020 , 71, e45-e49	11.6	4
46	The Effect of Infectious Diseases Consultation on Mortality in Hospitalized Patients With Methicillin-Resistant , , and Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa010	1	13
45	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa500	1	26
44	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 623-631	8	298
43	Correlation between Blood and CSF Compartment Cytokines and Chemokines in Subjects with Cryptococcal Meningitis. <i>Mediators of Inflammation</i> , 2020 , 2020, 8818044	4.3	2
42	Symptoms of COVID-19 Outpatients in the United States. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa271		21
41	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19-A Call for Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa350	1	19
40	Change in Plasma Cryptococcal Antigen Titer Is Not Associated With Survival Among Human Immunodeficiency Virus-infected Persons Receiving Preemptive Therapy for Asymptomatic Cryptococcal Antigenemia. <i>Clinical Infectious Diseases</i> , 2020 , 70, 353-355	11.6	2
39	Cryptococcal Antigen Screening and Preemptive Treatment-How Can We Improve Survival?. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1691-1694	11.6	9
38	Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines. <i>Clinical Infectious Diseases</i> , 2020 , 70, 754-762	11.6	20
37	Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. <i>Medical Mycology</i> , 2020 , 58, 282-292	3.9	1
36	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa130	1	122
35	The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015-2017. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz419	1	20
34	New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs. <i>Clinical Infectious Diseases</i> , 2019 , 69, 732	11.6	3
33	Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model. <i>Open Forum Infectious Diseases</i> , 2019 , 6,	1	10
32	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019 , 9, e026288	3	3
31	Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 182-189	3.1	24
30	Female Contributions to Infectious Diseases Society of America Guideline Publications. <i>Clinical Infectious Diseases</i> , 2019 , 68, 893-894	11.6	4

29	Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis. <i>PLoS ONE</i> , 2019 , 14, e0210105	3.7	25
28	HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. <i>Journal of Infectious Diseases</i> , 2019 , 219, 877-883	7	27
27	Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	57
26	A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 231-238	3.1	19
25	Successful Conservative Management of Bilateral Renal Mucormycosis. <i>Urology</i> , 2018 , 120, 2-5	1.6	1
24	Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. <i>Wellcome Open Research</i> , 2018 , 3, 64	4.8	16
23	Evaluation of a point-of-care immunoassay test kit StrongStep for cryptococcal antigen detection. <i>PLoS ONE</i> , 2018 , 13, e0190652	3.7	18
22	A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda. <i>Medicine (United States)</i> , 2018 , 97, e11722	1.8	6
21	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 873-881	25.5	986
20	Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program. <i>Clinical Infectious Diseases</i> , 2017 , 65, 2126-2129	11.6	39
19	Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. <i>BMC Infectious Diseases</i> , 2017 , 17, 225	4	18
18	Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts. <i>BMC Neurology</i> , 2017 , 17, 110	3.1	11
17	Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006-2016. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx077	1	9
16	HIV care: ART adherence support and cryptococcal screening. <i>Lancet, The</i> , 2015 , 385, 2128-9	40	6
15	Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. <i>Current Tropical Medicine Reports</i> , 2015 , 2, 81-89	5	35
14	Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv157	1	12
13	Epidemiology of meningitis in an HIV-infected Ugandan cohort. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 92, 274-9	3.2	51
12	Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. <i>New England Journal of Medicine</i> , 2014 , 370, 2487-98	59.2	304

11	Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 . <i>PLoS ONE</i> , 2014 , 9, e103156	3.7	19
10	Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. <i>Emerging Infectious Diseases</i> , 2014 , 20, 45-53	10.2	193
9	The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1607-14	11.6	108
8	Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. <i>Metabolic Brain Disease</i> , 2014 , 29, 269-279	3.9	31
7	Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 . <i>Clinical Infectious Diseases</i> , 2012 , 55, 1742-4	11.6	23
6	Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, e85-91	3.1	113
5	Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. <i>PLoS Medicine</i> , 2012 , 9, e1001316	11.6	63
4	Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. <i>Open Forum Infectious Diseases</i> ,	1	78
3	Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: Study Protocol for a Pragmatic Randomized Controlled Trial		1
2	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 6 , 140	4.8	0
1	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 6 , 140	4.8	